Sign In
Buy ATOS
$4.70
-0.150 (-3.09%)
At Close: Jun 03, 2026
Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on bre
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
01:30pm, Wednesday, 13'th May 2020
SEATTLE, May 13, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of.
Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment
01:30pm, Thursday, 07'th May 2020
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus
Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs
12:00pm, Thursday, 07'th May 2020
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus
Atossa Genetics (NASDAQ:ATOS) Research Coverage Started at Maxim Group
07:16am, Wednesday, 29'th Apr 2020
Analysts at Maxim Group assumed coverage on shares of Atossa Genetics (NASDAQ:ATOS) in a report issued on Tuesday, TipRanks reports. The brokerage set a “buy” rating and a $4.00 price target on th
Atossa Genetics (ATOS) Gets a Buy Rating from Maxim Group
05:16pm, Tuesday, 28'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS) today and set a price target of $4.00. The company's shares closed last
Atossa Genetics (ATOS) Gets a Buy Rating from Maxim Group
05:16pm, Tuesday, 28'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Atossa Genetics (ATOS – Research Report) today and set a
Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study
12:00pm, Monday, 27'th Apr 2020
Atossa Therapeutics, Inc. (ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need, today announced that it ha
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s
Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’
07:40pm, Wednesday, 22'nd Apr 2020
The world’s focus has zeroed in on healthcare companies. Hardly a surprising turn of events in these pandemic driven times. The search for a treatment or vaccine for COVID-19 has thrust into the lim
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
12:00pm, Monday, 20'th Apr 2020
Atossa Therapeutics, Inc. (ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 patients on mechanical ventilation. AT-H201 is a novel
Atossa Genetics (NASDAQ:ATOS) Rating Reiterated by Maxim Group
07:18am, Saturday, 18'th Apr 2020
Atossa Genetics (NASDAQ:ATOS)‘s stock had its “buy” rating reissued by equities researchers at Maxim Group in a research report issued to clients and investors on Friday, TipRanks reports. They
Atossa Genetics (ATOS) Receives a Buy from Maxim Group
04:47pm, Friday, 17'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Genetics (ATOS), with a price target of $4.00. The company's
Atossa Genetics (ATOS) Receives a Buy from Maxim Group
04:47pm, Friday, 17'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Genetics (ATOS – Research
COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted
02:51pm, Friday, 17'th Apr 2020
Physician-scientist and inventor Dr. Steven Quay, MD, PhD announced today that his proprietary model of COVID-19 case growth predicts that the United States as a whole will be able to declare a SARS-C
